The European Medical Cannabis Association – the Brussels-based industry body – calls for harmonised EU regulatory framework to create equal access for patients

Promoted content

This article is part of our special report Shedding light on medical cannabis.

The European Medicinal Cannabis Association (EUMCA), the newly formed Brussels-based industry body, represents the interests of ethical companies working in the supply and manufacturer of medicinal cannabis.

Incorporated on 14th November 2019, the EUMCA advocates for European evidence-based policy to improve patient access to high-quality cannabis treatment.  Its aim is to create a supportive and harmonised EU regulatory environment in which producers and manufacturers sign up to good manufacturing practices (GMP) and deliver medicinal cannabinoid treatments that conform with acknowledged scientific standards of quality, safety and efficacy.

An example of this is Tilray, a producer of medical cannabis treatments, and the first GMP-certified company to develop such medications. They are a global leader in cannabis research, cultivation, processing, and distribution and aspire to lead, legitimise and define the future of the medical cannabis industry by building the world’s most trusted cannabis company, and to increase patient access.


Learn more about the EUMCA by visiting their site:

Learn more about Tilray:

Subscribe to our newsletters